Key facts
- This page summarizes Brent Warner's Form 4 filing for Poseida Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2024, 17:18.
Brent Warner - 01 Mar 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.
- Reporting relationship
- President, Gene Therapy
- Issuer ticker
- N/A
- Reported as of
- 01 Mar 2024
- Net transaction value
- -$147,602
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2024, 17:18:30 UTC
- Prior SEC filing
- 02 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry J.Leonhardt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brent Warner filed Form 4 for Poseida Therapeutics, Inc. on 04 Mar 2024.
Change
- Previous filing in this sequence was filed on 02 Mar 2023.
- Current net transaction value: -$147,602.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PSTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +80,743
- Change %
- +22%
- Price
- $0.000000
- Shares after
- 454,779
- Date
- 01 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
PSTX
transaction
Common Stock
Tax liability
- Transaction value
- $147,602
- Shares
- -35,739
- Change %
- -7.9%
- Price
- $4.13
- Shares after
- 419,040
- Date
- 01 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PSTX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +111,700
- Change %
- Price
- $0.000000
- Shares after
- 111,700
- Date
- 01 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 111,700
- Exercise price
- $4.13
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
Footnote F2
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
Footnote F3
12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.